Phase II Trial of VDJ001 in Patients With Moderate-to-severe Active Rheumatoid Arthritis

PHASE2CompletedINTERVENTIONAL
Enrollment

181

Participants

Timeline

Start Date

May 26, 2022

Primary Completion Date

June 2, 2023

Study Completion Date

June 2, 2023

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

Recombinant Humanized Anti-interleukin-6 Receptor Monoclonal Antibody Injection

The drug was administered once every 4 weeks.

Trial Locations (15)

010000

Peking University People's Hospital, Beijing

Unknown

Baoji Central Hospital, Baoji

Beijing Hospital, Beijing

The First Affiliated Hospital of Bengbu Medical College, Bengbu

Chenzhou First People's Hospital, Chenzhou

Pingxiang People's Hospital, Jiangxi

Jilin Province People's Hospital, Jilin

Affiliated Hospital of North Sichuan Medical College, Nanchong

Drum Tower Hospital Affiliated to Nanjing University Medical School, Nanjing

Puyang Oilfield General Hospital, Pujiang

Qilu Hospital of Shandong University, Shandong

Peking University Shenzhen Hospital, Shenzhen

People's Hospital of Xinjiang Uygur Autonomous Region, Xinjiang

Zaozhuang Municipal Hospital, Zaozhuang

The First Affiliated Hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

Beijing VDJBio Co., LTD.

INDUSTRY